CytRx

CytRx Corporation Relaunches as LadRx Corporation

Retrieved on: 
Friday, September 23, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Centurion, CytRx, Therapy, Cancer, Niemann–Pick disease, Neoplasm, LADR, IND, Antibody, Nature, Company, OTCQB, Pancreatic cancer, NPC, Melanoma, Patient, CEO, ImmunityBio, Leadership, Doctor of Philosophy, Research, Immunity, SEC, Gaucher's disease, Annual report, Toxicity, Pharmaceutical industry, Aldoxorubicin

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.
  • We are now pleased to announce the relaunch of the Company under the name LadRx Corporation.
  • All forward-looking statements are based upon information available to the CytRx on the date the statements are first published.
  • CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer.

European Patent Office Awards CytRx Key Patent

Retrieved on: 
Wednesday, September 7, 2022
Oncology, Health, Health Technology, Other Health, General Health, Pharmaceutical, Biotechnology, LADR, Technology, Cancer, Research, ImmunityBio, CytRx, Niemann–Pick disease, Gaucher's disease, NPC, Toxic leukoencephalopathy, SEC, European Patent Office, Patent, Company, Therapy, Failure, European Patent Convention, Annual report, OTCQB, Forward-looking statement, Patient, Nature, Pharmaceutical industry

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.
  • CytRx notes that a US patent US Patent No.
  • 11,384,104 covering the LADR platform has also recently been issued, which when combined with the European patent results in broad international protection of this important new technology.
  • In addition to intellectual property to protect the LADR platform, CytRx has also pursued patent protection covering certain specific drugs that incorporate the LADR backbone.

Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer

Retrieved on: 
Monday, August 22, 2022
Amyotrophic lateral sclerosis, National Association, CEO, Pain, Research, Stilley, Addiction, Adenosine, Maintenance, U.S. Securities and Exchange Commission, GLOBE, Leadership, Company, Sucampo Pharmaceuticals, M.B.A, Patient, Inflammation, EMA, Telephone, Cancer, Obesity, Business administration, Time, CytRx, Sale, Fatty liver disease, Board, EDT, CFO, FDA, Rutgers University, Communication, Diabetes, Director, Partnership, Security (finance), Corporation, Therapy, NASDAQ, Villanova University, AUD, Vice, Drinking, Gambling, Growth, Health, National Association of Corporate Directors, Marketing, Nature, NACD, Asthma, Infection, NASH, Annual report, Eye, Perfume, Pharmaceutical industry, Indivior, Nasdaq, Mallinckrodt

CHARLOTTESVILLE, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the appointment of Cary J. Claiborne as President and Chief Executive Officer. Mr. Claiborne, who has 18 years of experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies, takes over the role of William Stilley, who was appointed to the newly created position of CEO of Purnovate, Inc. Both executives will remain on the Board of Directors of Adial. The Company also announced that Kevin Schuyler, who has served as Vice Chairman and as an independent director, has been appointed Chairman.

Key Points: 
  • Mr. Claiborne was appointed Chief Operating Officer of Adial in December 2022 after previously being named to the Board of Directors.
  • Most recently, Mr. Claiborne served as Chief Financial Officer and director of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses.
  • Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt.
  • As CEO, Cary brings extensive experience as an executive and board member with other commercial stage biopharma businesses.

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

Retrieved on: 
Tuesday, August 9, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, FDA, ImmunityBio, CEO, Forward-looking statement, Failure, SEC, Cancer, PLC, Board, Achievement, Research, Aldoxorubicin, Rutgers University, CytRx, Niemann–Pick disease, Financial compensation, Patient, Therapy, Villanova University, NPC, Nature, Gaucher's disease, OTCQB, Business administration, Professional Football Compensation Committee, LADR, Annual report, EMA, Management, Pharmaceutical industry, IND

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the Board").

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the Board").
  • Mr. Claiborne brings to CytRx a wealth of experience in public company governance, finance and operational management.
  • Prior to joining Adial, Mr. Claiborne served as the Chief Financial Officer and board director at Indivior, PLC, a public global commercial-stage pharmaceutical company.
  • From 2011 to 2014, Mr. Claiborne was the Chief Financial Officer of Sucampo Pharmaceuticals, Inc., a public commercial-stage biopharmaceutical company.

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

Retrieved on: 
Thursday, May 19, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Company, CytRx, Niemann–Pick disease, Securities and Exchange Commission (Nigeria), ImmunityBio, Annual report, Patient, Venture round, Nature, Delaware General Corporation Law, Research, FDA, Industry, EMA, Board, Forward-looking statement, Proxy, Board of directors, NPC, Therapy, Gaucher's disease, SEC, Growth, Cancer, OTCQB, Security (finance)

Subject to certain limitations, each outstanding share of Series D Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series D Preferred Stock).

Key Points: 
  • Subject to certain limitations, each outstanding share of Series D Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series D Preferred Stock).
  • The Series D Preferred Stock will be uncertificated, and no shares of Series D Preferred Stock will be transferable by any holder thereof except in connection with a transfer by such holder of any shares of the Companys common stock held by such holder.
  • In that case, a number of one one-thousandths of a share of Series D Preferred Stock equal to the number of shares of the Companys common stock to be transferred by such holder would be transferred to the transferee of such shares of common stock.
  • Further details regarding the Series D Preferred Stock will be contained in a report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.

CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

Retrieved on: 
Tuesday, May 17, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Death, Niemann–Pick disease, CytRx, Idiopathic hypersomnia, ImmunityBio, Annual report, Doctor of Philosophy, Neurodegeneration, Patient, Lipid, Nature, USD, CRL, Research, FDA, CNS, Cholesterol, Forward-looking statement, EMA, Central nervous system, NPC, NDA, Arimoclomol, Therapy, Acquisition, SEC, Cancer, OTCQB, Pharmaceutical industry

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (KemPharm).

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (KemPharm).
  • Under the terms of the agreement, KemPharm will purchase substantially all of the assets and operations of Orphazyme, including arimoclomol, for a cash payment of USD $12.8 million.
  • CytRx licensed arimoclomol to Orphazyme for milestones and royalties on sales, and CytRx expects the terms of its license with Orphazyme to remain intact as the arimoclomol asset transfers to KemPharm.
  • All forward-looking statements are based upon information available to the CytRx on the date the statements are first published.

Arcellx Appoints Olivia Ware to Board of Directors

Retrieved on: 
Monday, May 16, 2022
Senior, Physician, Multiple myeloma, Acute myeloid leukemia, Knowledge, Engineering, CytRx, Medicine, Regulation of tobacco by the U.S. Food and Drug Administration, Food, U.S. Securities and Exchange Commission, Sanofi, Risk, Leadership, Davidson College, Patient, NASDAQ, Regenerative medicine, Therapy, Trastuzumab, Marketing, MM, Chapel Hill, Securities Act of 1933, Securities Exchange Act of 1934, Board, Rituximab, University, Genentech, Board of directors, Bevacizumab, Drug Quality and Security Act, Drug development, Cancer, Security (finance), Principia, University of North Carolina at Greensboro, Pharmaceutical industry, Management

FOSTER CITY, Calif., May 16, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Olivia Ware to its Board of Directors. Ms. Ware, a successful executive, brings a wealth of knowledge from her more than 20 years of experience in biotech and pharmaceutical drug development, commercialization, and healthcare management.

Key Points: 
  • "On behalf of our entire Board, I'd like to thank Rusty for his many contributions to Arcellx as both a private and publicly traded biotech company.
  • "Olivia's deep industry and commercialization expertise will be an invaluable addition to the existing depth of experience on our Board.
  • Arcellx's lead product candidate, CART-ddBCMA, has the potential to be a meaningful treatment option for patients diagnosed with multiple myeloma, an incurable disease," said Olivia Ware.
  • Ms. Ware replaces Lewis T. "Rusty" Williams, M.D., co-founder, chairman and chief executive officer of Walking Fish Therapeutics, who has served on Arcellx's Board of Directors since 2019.

CytRx Partners with Oncology Development Expert to Advance LADR Platform

Retrieved on: 
Wednesday, April 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Drug development, Board, Nature, Annual report, Investigational New Drug, LADR, IND, University of Washington Department of Bioengineering, Niemann–Pick disease, LLC, CytRx, Business administration, Initial public offering, ImmunityBio, Master of Business Administration, Research, Toxicity, Gaucher's disease, MD, Pancreatic cancer, NPC, Patient, Harvard College, Clinical Associate (Psychology), Neoplasm, University of Colorado School of Medicine, Failure, Death, Company, OTCQB, SEC, Forward-looking statement, Takeda Pharmaceutical Company, Antibody, Doxorubicin, Disease, Harvard Medical School, University, Partnership, Therapy, Cancer, Internal medicine, Drug discovery, Pharmaceutical industry, Aldoxorubicin, Medicine

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.
  • Dr. Gordon is President of ORRA Group, LLC, a consultancy focused on assisting companies in drug development efforts, particularly in oncology.
  • Dr. Gordon brings 30 years of experience in the development of oncology therapeutics, having led clinical teams in multi-national Phase I through Phase III trials.
  • The difficult market environment has not impacted our confidence in LADR or our resolve to unlock shareholder value through advancement of our LADR-based drugs.

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

Retrieved on: 
Monday, March 21, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Centurion, Company, Common stock, Niemann–Pick disease, Therapy, Forward-looking statement, CytRx, LADR, Board, ImmunityBio, Annual report, Galena Biopharma, Research, SEC, Cancer, Failure, Gaucher's disease, Board of directors, Communication, Armistice, NPC, Sustainability Accounting Standards Board, Annual general meeting, OTCQB, Maintenance, Nature, Indian stock exchange, Pancreatic cancer, Patient, Pharmaceutical industry, Aldoxorubicin

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to stockholders.

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to stockholders.
  • As we stated at the start of this year, it is the beginning of a new day at CytRx.
  • These valuable assets belong 100% to CytRx stockholders, so we have folded Centurion BioPharma and the LADR assets into CytRx.
  • We greatly appreciate that approximately 73% of stockholders who voted at our recent special meeting supported this important proposal.

CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates

Retrieved on: 
Wednesday, March 9, 2022
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Centurion, LADR, Annual general meeting, CytRx, Annual report, Company, Research, U.S. Securities and Exchange Commission, Therapy, Achievement, FDA, Failure, Niemann–Pick disease, Cancer, EMA, OTCQB, Nature, Board, Forward-looking statement, Patient, NPC, Security (finance), Form, Pancreatic cancer, Doctor of Philosophy, Gaucher's disease, SEC, Pharmaceutical industry, ImmunityBio, Aldoxorubicin

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that the Company is absorbing its wholly-owned subsidiary Centurion BioPharma Corporation (Centurion).

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that the Company is absorbing its wholly-owned subsidiary Centurion BioPharma Corporation (Centurion).
  • CytRx thanks Dr. Ignarro and Mr. Kriegsman for their many years of service and wishes them well in their future pursuits.
  • A new independent director will be added to the Board at or before the 2022 Annual Meeting of Shareholders.
  • All forward-looking statements are based upon information available to the CytRx on the date the statements are first published.